主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VTGN
#4002
Vistagen Therapeutics, Inc. Common Stock
0.607
3
USD
-3.73%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
-3.73%
每月变动
+17.90%
6个月变化
+17.90%
年变化
+17.90%
前一天收盘价
0.630
8
Open
0.607
3
Bid
0.607
3
Ask
0.610
3
Low
0.607
3
High
0.607
3
交易量
6
市场
股票
医疗保健
VTGN
Open full chart
Financials
Overview
声明
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
6.38 M
6.89 M
7.87 M
27.03 M
29.16 M
—
Valuation ratios
Enterprise value
—
—
—
26.74 M
5.76 M
74.42 M
Price to earnings ratio
—
—
—
-3.55
-1.5
-4.82
Price to sales ratio
—
—
—
98.23
158.83
443.43
Price to cash flow ratio
—
—
—
-4.05
-1.83
-5.63
Price to book ratio
—
—
—
0.91
1.1
1.81
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.17
0.64
2.81
0.24
0.61
0.91
Return on equity %
0.19
0.74
4.9
0.26
0.73
1.12
Return on invested capital %
1 363.97
3 390.02
4 642.81
2 867.66
4 598.63
5 050.58
Gross margin %
100
100
100
100
100
400
Operating margin %
1 646.06
4 308.3
26.11 K
3 103.48
11.52 K
96.99 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 646.09
4 306.76
26.1 K
2 759.59
10.58 K
91.71 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
24.85
12.32
3.83
23.55
6.51
22.95
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.02
0.01
0
0.01
0
0.01
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0
—
—
0
—
—
Long term debt to total equity ratio
0
—
—
0
—
—
Per share metrics
Operating cash flow per share
—
-6.86
-7.14
1.33
1.36
1.72
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
10.32
2.39
6.16
2.61
8.21
Net current asset value per share
—
10.76
2.52
6.23
2.66
8.45
Tangible book value per share
—
9.81
1.74
5.9
2.28
7.12
Working capital per share
—
9.88
1.86
5.97
2.25
6.99
Book value per share
—
9.81
1.74
5.9
2.28
7.12
新闻
Vistagen Therapeutics裁员20%以控制成本
Vistagen Therapeutics reduces workforce by 20 percent to manage costs
VistaGen在TD Cowen大会上展示:聚焦信息素平台技术
VistaGen at TD Cowen Conference: Pherine Platform in Focus
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
VistaGen Therapeutics 2026年第三季度财报电话会议:AI驱动的试验分析亮点
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
Vistagen Therapeutics公司的fasedienol三期临床试验未达终点
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47%
美国股市收低;截至收盘道琼斯工业平均指数下跌0.47%